SCHEMBL7097193

SCHEMBL7097193

Cc1ccc(CC2CCN(CCCc3nc4ccccc4[nH]3)CC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 6/20 0.62
GRIN1 Q05586 3/20 0.62
GRIN2A Q12879 2/20 0.58
GRIN2C Q14957 1/20 0.58
CHRNA7 P36544 1/20 0.54
HTR1A P08908 2/20 0.52
HTR7 P34969 2/20 0.52
DRD2 P14416 2/20 0.52
DRD3 P35462 2/20 0.52
HRH1 P35367 1/20 0.52
DRD4 P21917 1/20 0.52
POLB P06746 1/20 0.48
CCR3 P51677 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
PARP1 P09874 1/20 0.47
PARP2 Q9UGN5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7102398 0.91 GRIN2B (0.74) GRIN2BGRIN1GRIN2AGRIN2CCHRNA7
SCHEMBL7098942 0.89 GRIN2B (0.62) GRIN2BGRIN1GRIN2AGRIN2CCHRNA7
SCHEMBL5333493 0.84 CHRNA7 (0.60) GRIN2BGRIN1GRIN2AGRIN2CCHRNA7
SCHEMBL5335558 0.82 CHRNA7 (0.58) GRIN2BGRIN1GRIN2AGRIN2CCHRNA7
SCHEMBL5337358 0.82 CHRNA7 (0.62) GRIN2BGRIN1CHRNA7HTR1AHTR7
SCHEMBL5334974 0.81 CHRNA7 (0.57) GRIN2BGRIN1GRIN2AGRIN2CCHRNA7
SCHEMBL7099313 0.79 GRIN2B (0.57) GRIN2BGRIN1GRIN2AGRIN2CHTR1A
SCHEMBL9518726 0.78 DRD2 (0.67) CHRNA7HTR1AHTR7DRD2DRD3
SCHEMBL7099798 0.77 GRIN2B (0.54) GRIN2BGRIN1GRIN2AGRIN2CCHRNA7
SCHEMBL5338493 0.77 CHRNA7 (0.70) GRIN2BGRIN1GRIN2ACHRNA7HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030018038-A1 1,4 substituted piperidinyl NMDA/NR2B antagonists MERCK & CO., INC. 2003-01-23 US claimed
US-6476041-B1 1,4 substituted piperidinyl NMDA/NR2B antagonists MERCK & CO., INC. 2002-11-05 US claimed
EP-1235798-A4 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-04-23 EP disclosed
US-20030018038-A1 1,4 substituted piperidinyl NMDA/NR2B antagonists MERCK & CO., INC. 2003-01-23 US disclosed
US-6476041-B1 1,4 substituted piperidinyl NMDA/NR2B antagonists MERCK & CO., INC. 2002-11-05 US disclosed
EP-1235798-A1 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-09-04 EP disclosed
WO-2001032615-A1 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018038-A1 1,4 substituted piperidinyl NMDA/NR2B antagonists GRIN1, GRIN2A, GRIN2B GRIN2B 3/4885GRIN1 1/4885GRIN2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.